CI-994
CI-994 structure
|
Common Name | CI-994 | ||
|---|---|---|---|---|
| CAS Number | 112522-64-2 | Molecular Weight | 269.298 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 450.6±30.0 °C at 760 mmHg | |
| Molecular Formula | C15H15N3O2 | Melting Point | 242 °C(dec.) | |
| MSDS | Chinese USA | Flash Point | 226.3±24.6 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of CI-994CI-994 (Tacedinaline) is an inhibitor of the histone deacetylase (HDAC) with IC50s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively. |
| Name | 4-acetamido-N-(2-aminophenyl)benzamide |
|---|---|
| Synonym | More Synonyms |
| Description | CI-994 (Tacedinaline) is an inhibitor of the histone deacetylase (HDAC) with IC50s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively. |
|---|---|
| Related Catalog | |
| Target |
HD1:0.9 μM (IC50) HD2:0.9 μM (IC50) HD3:1.2 μM (IC50) |
| In Vitro | CI-994 (N-acetyldinaline) is a novel oral compound with a wide spectrum of antitumor activity in preclinical models. The mechanism of action may involve inhibition of histone deacetylation and cell cycle arrest. CI-994 is combined with antineoplastic agents commonly used in non-small cell lung cancer cell line management, a marked synergism of action (R=1.8, R=1.5) is observed between CI-994 (40 μM) and gemcitabine (0.01 μM) at 48 and 72 h of treatment[2].CI-994 inhibits mitogen-stimulated blood lymphocyte proliferation with an IC50 value of 3 μM[4]. |
| In Vivo | CI-994 has activity against 8/8 solid tumors tested: pancreatic ductal adenocarcinoma #02 (4.7); pancreatic adenocarcinoma #03 (3.0; 1/6 cures); colon adenocarcinoma #38 (1.6); colon adenocarcinoma #51/A (1.1); mammary adenocarcinoma #25 (1.7); mammary adenocarcinoma #17/ADR (0.5); Dunning osteogenic sarcoma (4.0); and the human prostate carcinoma LNCaP (1.2). CI-994 is the acetylated metabolite of dinaline and has the same spectrum of activity in vivo as dinaline. It also behaves similarly in schedule comparison/toxicity trials[3]. CI-994 can effect lymphoid tissue in rats within 1 day of a single oral dose, that effects are generally reversible within 7 days[4]. |
| Animal Admin | Rats: To characterize the effects of CI-994 on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue[4]. |
| References |
[3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 450.6±30.0 °C at 760 mmHg |
| Melting Point | 242 °C(dec.) |
| Molecular Formula | C15H15N3O2 |
| Molecular Weight | 269.298 |
| Flash Point | 226.3±24.6 °C |
| Exact Mass | 269.116425 |
| PSA | 84.22000 |
| LogP | 0.96 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.707 |
|
~96%
CI-994 CAS#:112522-64-2 |
| Literature: THE BROAD INSTITUTE, INC.; Holson, Edward; Wagner, Florence F.; Stahly, G. Patrick Patent: US2013/102677 A1, 2013 ; Location in patent: Paragraph 0127; 0128; 0129 ; |
|
~80%
CI-994 CAS#:112522-64-2 |
| Literature: Thomas, Mickael; Clarhaut, Jonathan; Tranoy-Opalinski, Isabelle; Gesson, Jean-Pierre; Roche, Joelle; Papot, Sebastien Bioorganic and Medicinal Chemistry, 2008 , vol. 16, # 17 p. 8109 - 8116 |
|
~92%
CI-994 CAS#:112522-64-2 |
| Literature: THE BROAD INSTITUTE, INC.; HOLSON, Edward; WAGNER, Florence; STAHLY, G., Patrick Patent: WO2012/3413 A1, 2012 ; Location in patent: Page/Page column 52-53 ; |
|
~%
CI-994 CAS#:112522-64-2 |
| Literature: WO2012/3413 A1, ; |
|
~%
CI-994 CAS#:112522-64-2 |
| Literature: WO2012/3413 A1, ; |
|
~%
CI-994 CAS#:112522-64-2 |
| Literature: WO2012/3413 A1, ; |
|
~%
CI-994 CAS#:112522-64-2 |
| Literature: WO2012/3413 A1, ; |
|
~%
CI-994 CAS#:112522-64-2 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 16, # 17 p. 8109 - 8116 |
|
~%
Detail
|
| Literature: Bioorganic and Medicinal Chemistry, , vol. 16, # 17 p. 8109 - 8116 |
![6-[2-(4-acetylamino-benzoylamino)-phenylcarbamoyloxy]-3,4,5-trihydroxy-tetrahydro-2H-pyran-2-carboxylic acid structure](https://www.chemsrc.com/caspic/471/1075719-58-2.png)
![6-{4-[(2-(4-acetylamino-benzoylamino)-phenylcarbamoyl)oxymethyl]-2-nitro-phenoxy}-tetrahydro-2H-pyran-2-carboxylic acid structure](https://www.chemsrc.com/caspic/009/1075719-57-1.png)
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline).
Int. J. Cancer 62(5) , 636-42, (1995) The mechanism of action of the novel anti-cancer compound CI-994 was studied in C26 murine colon tumor and HCT-8 human colon adenocarcinoma cells. Treatment of either cell line resulted in the specifi... |
|
|
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Cancer Invest. 22(6) , 886-96, (2004) To determine maximum tolerated dose of CI-994, a novel oral histone deacetylase inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.Patients with advanced ... |
|
|
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
Clin. Cancer Res. 6(6) , 2474-81, (2000) Dose intensity, defined as dose administered per unit time, has emerged as a potentially important measurement of anticancer drug exposure and determinant of efficacy. There are several strategies for... |
| Tacedinaline |
| 4-Acetamido-N-(2-aminophenyl)benzamide |
| 4-(Acetylamino)-N-(2-aminophenyl)benzamide |
| Goe 5549 |
| N-acetyldinaline |
| Acetyldinaline |
| Tacedinalina |
| Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- |
| CI994 |
| CI-994 |